All In Biotech

Drug Trial Radar · NCT04888741

Methods of T Cell Depletion Trial (MoTD)

A Multi-centre Phase II Trial of GVHD Prophylaxis Following Unrelated Donor Stem Cell Transplantation Comparing Thymoglobulin vs. Calcineurin Inhibitor or Sirolimus-based Post-transplant Cyclophosphamide

Last checked: Nov 20, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Feb 22, 2021

Primary completion

Aug 23, 2027

Study completion Aug 23, 2027

Sponsor

Lead sponsor
University of BirminghamAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Jon Moulton Charity Trust; IMPACT (funded by NHS Blood & Transplant, Anthony Nolan and Leukaemia UK)
First posted
May 17, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 16 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multi-centre phase II trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin vs. Calcineurin inhibitor or Sirolimus-based post-transplant cyclophosphamide.

Conditions

  • Acute Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Chronic Myelomonocytic Leukemia
  • Myelodysplastic Syndromes
  • Non Hodgkin Lymphoma
  • Hodgkin Lymphoma
  • Multiple Myeloma
  • Chronic Myelogenous Leukemia
  • Myelofibrosis

Interventions

  • ThymoglobulinDrug

    GVHD prophylaxis

  • CyclophosphamideDrug

    Post transplant cyclophosphamide strategy for GVHD prophylaxis

  • CyclosporineDrug

    immunosuppressant

  • SirolimusDrug

    immunosuppressant

  • Mycophenolate MofetilDrug

    immunosuppressant

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. GVHD-free, relapse-free survivalTime frame: at 1 year

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Queen Elizabeth Hospital

    Birmingham, United Kingdom · Recruiting

  • Bristol Haematology and Oncology Centre

    Bristol, United Kingdom · Recruiting

  • Addenbrookes Hospital

    Cambridge, United Kingdom · Recruiting

  • Queen Elizabeth Hospital Glasgow

    Glasgow, United Kingdom · Recruiting

  • St Jame's University Hospital

    Leeds, United Kingdom · Recruiting

  • University College London Hospital

    London, United Kingdom · Recruiting

  • King's College Hospital

    London, United Kingdom · Recruiting

  • Hammersmith Hospital

    London, United Kingdom · Recruiting

  • Manchester Royal Infirmary

    Manchester, United Kingdom · Recruiting

  • The Christie

    Manchester, United Kingdom · Recruiting

  • Freeman Hospital

    Newcastle upon Tyne, United Kingdom · Recruiting

  • Nottingham City Hospital

    Nottingham, United Kingdom · Recruiting

  • Churchill Hospital

    Oxford, United Kingdom · Recruiting

  • Derriford Hospital

    Plymouth, United Kingdom · Recruiting

  • Royal Hallamshire Hospital

    Sheffield, United Kingdom · Recruiting

  • The Royal Marsden Hospital

    Sutton, United Kingdom · Recruiting

  • University Hospital of Wales

    Cardiff, Wales, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.